SRPT Sarepta Therapeutics (SRPT) Insider Trading, Ownership & Congress Trades
Pharma & Biotech · Pharmaceutical preparations · CIK 0000873303
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
154
13F, latest reported quarter
What the filings say about SRPT
Congress, 1 year
No trades
Last one: sale, 2025-04-14
Sarepta Therapeutics insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
No insider purchases or sales are on record for Sarepta Therapeutics, Inc. in the period covered. Source: SEC Form 4 filings, as of 2026-10-28.
Insider
Filed
Shares
Value
Since filing
Context
- 2 earlier Form 4 trades (code P or S) here by this insider (2 sales), the last on Mar 5, 2024.
- The trade is 410.1% of the 1,765 shares held after it.
- No other insider sold within 30 days.
- 154 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Mayo Stephen sold about $123.2K of SRPT on Mar 12, 2026; 154 funds added in the latest 13F quarter.Context
- 2 earlier Form 4 trades (code P or S) here by this insider (2 sales), the last on Aug 30, 2024.
- The trade is 6.8% of the 193,300 shares held after it.
- No other insider sold within 30 days.
- 154 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Operating Officer Estepan Ian Michael sold about $294.2K of SRPT on Dec 16, 2025, the largest insider sale at the company since 2024; 154 funds added in the latest 13F quarter.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 9.0% of the 27,812 shares held after it.
- No other insider sold within 30 days.
- 154 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Nicaise Claude sold about $248.2K of SRPT on Mar 12, 2025; 154 funds added in the latest 13F quarter.Context
- 4 earlier Form 4 trades (code P or S) here by this insider (4 sales), the last on Mar 8, 2024.
- The trade is 46.0% of the 22,840 shares held after it.
- 1 other insider sold within 30 days.
- 154 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Wigzell Hans Lennart Rudolf sold about $1.3M of SRPT on Dec 12, 2024; 1 other insider sold within 30 days and 154 funds added in the latest 13F quarter.Context
- 1 earlier Form 4 trade (code P or S) here by this insider (1 sale), the last on Mar 11, 2024.
- The trade is 27.8% of the 5,880 shares held after it.
- 1 other insider sold within 30 days.
- 154 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Boor Kathryn Jean sold about $205.4K of SRPT on Dec 5, 2024; 1 other insider sold within 30 days and 154 funds added in the latest 13F quarter.53 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
no insider buys or sells on file
Congress
no House purchase disclosed in the last 12 months
Funds
154 funds bought in last quarter
more than 83% of Pharma & Biotech
Revenue
+4.3% year over year
more than 51% of Pharma & Biotech
Margin
-38.3% net margin
more than 53% of Pharma & Biotech
Buybacks
$25.0M repurchased, FY to 2025-12-31
below 57% of Pharma & Biotech
Short interest
22.2% of the float short (float per yahoo 2026-10-27) · 7.5 days to cover · settled 2026-10-15
more than 95% of Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days
Watch SRPT
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-17.9%12M
Insider sell
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns SRPT: institutional holders (13F)
13F holdings, latest reported quarter
18,994,958 sh
$341.3M
8,916,090 sh
$160.2M
8,377,470 sh
$150.5M
4,598,735 sh
$82.6M
4,591,755 sh
$82.5M
Congress trades in SRPT
STOCK Act disclosures, US House only, filed up to 45 days after the trade
Sold 2025-04-14 · disclosed 22 days later
$1,001 - $15,000
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
SRPT planned insider sales (Form 144)
No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
SRPT mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
Moonvest ETF
$2.8M position · as of 2026-07-31
4.0%
First Trust NYSE Arca Biotechnology Index Fund
$64.4M position · as of 2026-06-30
2.3%
Invesco Biotechnology & Genome ETF
$6.2M position · as of 2026-07-31
2.2%
Global X Genomics & Biotechnology ETF
$1.0M position · as of 2026-05-31
1.8%
Virtus Biotech Etf
$1.3M position · as of 2026-07-31
1.3%
ALPS Medical Breakthroughs ETF
$1.9M position · as of 2026-05-31
1.2%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Clinical pipeline
28 registered trials, 13 still running (ClinicalTrials.gov).
A status change is dated here weeks before the press release.
7
Phase 1
3 active
2
Phase 2
0 active
8
Phase 3
4 active
1
Phase 4
1 active
3
Not applicable
3 active
7
Multi-phase
2 active
What changed recently
Study to Evaluate the Safety and Effectiveness of ELEVIDYS in Participants With Duchenne
2026-10-07 · Not Yet Recruiting → Recruiting
Phase 4
Study of SRP-1003 in Participants With Type 1 Myotonic Dystrophy
2026-10-06 · Recruiting → Enrolling By Invitation
PHASE1,PHASE2
Study of SRP-1001 in Adult and Adolescent Participants With Facioscapulohumeral Muscular
2026-10-06 · Recruiting → Enrolling By Invitation
PHASE1,PHASE2
Matched by sponsor name. Trials run under a subsidiary's
own name are not included.
Executive pay vs shareholder return
CEO pay, headline and as actually paid, against the company's
return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2025
$7.8M
-$17.3M
$3.8M
-87%
+25%
2024
$2.0M
-$14.5M
$2.7M
-29%
-6%
2023
$1.7M
-$34.6M
$3.6M
-43%
-6%
2022
$124.9M
$162.9M
$4.6M
-24%
-10%
2021
$1.5M
-$304.8M
$6.3M
-47%
+0%
Tagged by the company under SEC Item 402(v). Returns are
cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows 154 funds added last quarter. Each figure is a federal filing, dated the day it went public.
SRPT financials
Revenue growth
+4.3%
XBRL, annual
Net margin
-38.3%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$2.0B
four quarters, 2025-07-01 to 2026-06-30
Revenue, TTM SRPT
| FY Dec 2025 | $2.2B |
| FY Dec 2024 | $1.9B |
| FY Dec 2023 | $1.2B |
| FY Dec 2022 | $933.0M |
| FY Dec 2021 | $701.9M |
| Jun 2026 | $401.3M |
| Mar 2026 | $730.8M |
| Dec 2025 | $442.9M |
| Sep 2025 | $399.4M |
| Jun 2025 | $611.1M |
| Mar 2025 | $744.9M |
| Dec 2024 | $658.4M |
| Sep 2024 | $467.2M |
At each fiscal year end
Single quarter
Net margin, TTM
-6.9%
net income over revenue, 2025-07-01 to 2026-06-30
Net margin, TTM SRPT
| FY Dec 2025 | -32.5% |
| FY Dec 2024 | +12.4% |
| FY Dec 2023 | -43.1% |
| FY Dec 2022 | -75.4% |
| FY Dec 2021 | -59.7% |
| Jun 2026 | -1.2% |
| Mar 2026 | +45.3% |
| Dec 2025 | -93.1% |
| Sep 2025 | -12.7% |
| Jun 2025 | +32.2% |
| Mar 2025 | -60.1% |
| Dec 2024 | +24.2% |
| Sep 2024 | +7.2% |
At each fiscal year end
Single quarter
Free cash flow, TTM
$81.8M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM SRPT
| FY Dec 2025 | -$307.5M |
| FY Dec 2024 | -$342.7M |
| FY Dec 2023 | -$577.1M |
| FY Dec 2022 | -$356.2M |
| FY Dec 2021 | -$481.7M |
| Jun 2026 | $196.5M |
| Mar 2026 | -$204.8M |
| Dec 2025 | $127.6M |
| Sep 2025 | -$37.5M |
| Jun 2025 | $229.5M |
| Mar 2025 | -$627.1M |
| Dec 2024 | $54.0M |
| Sep 2024 | -$108.0M |
At each fiscal year end
Single quarter
Debt to equity
0.55x
LongTermDebt as filed 2026-06-30 (includes the current portion); equity 2026-06-30
Debt to equity SRPT
| FY Dec 2025 | 0.73x |
| FY Dec 2024 | 0.74x |
| FY Dec 2023 | 1.44x |
| FY Dec 2022 | 4.01x |
| FY Dec 2021 | 0.61x |
| Jun 2026 | 0.55x |
| Mar 2026 | 0.56x |
| Dec 2025 | 0.73x |
| Sep 2025 | 0.11x |
| Jun 2025 | 0.81x |
| Mar 2025 | 0.96x |
| Dec 2024 | 0.74x |
| Sep 2024 | 1.01x |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
0.13x
TTM operating cash flow over LongTermDebt as filed 2026-06-30 (includes the current portion)
Cash flow to debt SRPT
| FY Dec 2025 | -0.25x |
| FY Dec 2024 | -0.18x |
| FY Dec 2023 | -0.40x |
| FY Dec 2022 | -0.21x |
| FY Dec 2021 | -0.79x |
| Jun 2026 | 0.13x |
| Mar 2026 | 0.21x |
| Dec 2025 | -0.25x |
| Sep 2025 | -1.74x |
| Jun 2025 | -0.26x |
| Mar 2025 | -0.48x |
| Dec 2024 | -0.18x |
| Sep 2024 | -0.29x |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
-9.3%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity SRPT
| FY Dec 2025 | -53.5% |
| FY Dec 2024 | +19.7% |
| FY Dec 2023 | -86.2% |
| FY Dec 2022 | -107.2% |
| FY Dec 2021 | -49.6% |
| Jun 2026 | -9.3% |
| Mar 2026 | +4.8% |
| Dec 2025 | -53.5% |
| Sep 2025 | -11.2% |
| Jun 2025 | -4.7% |
| Mar 2025 | -23.1% |
| Dec 2024 | +19.7% |
| Sep 2024 | +12.3% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
-4.0%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets SRPT
| FY Dec 2025 | -19.5% |
| FY Dec 2024 | +6.5% |
| FY Dec 2023 | -16.8% |
| FY Dec 2022 | -22.4% |
| FY Dec 2021 | -13.7% |
| Jun 2026 | -4.0% |
| Mar 2026 | +2.0% |
| Dec 2025 | -19.5% |
| Sep 2025 | -4.0% |
| Jun 2025 | -1.6% |
| Mar 2025 | -7.4% |
| Dec 2024 | +6.5% |
| Sep 2024 | +3.6% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
pre-tax loss, no effective tax rate to apply
Return on invested capital SRPT
| FY Dec 2025 | n/a |
| FY Dec 2024 | +12.6% |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | +12.6% |
| Sep 2024 | +4.1% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
-5.3%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed SRPT
| FY Dec 2025 | -25.5% |
| FY Dec 2024 | +7.5% |
| FY Dec 2023 | -10.5% |
| FY Dec 2022 | -20.6% |
| FY Dec 2021 | -17.5% |
| Jun 2026 | -5.3% |
| Mar 2026 | -1.5% |
| Dec 2025 | -25.5% |
| Sep 2025 | -4.6% |
| Jun 2025 | -0.0% |
| Mar 2025 | -4.3% |
| Dec 2024 | +7.5% |
| Sep 2024 | +2.9% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
P/E, trailing SRPT
| FY Dec 2025 | n/a |
| FY Dec 2024 | 53.33x |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | 64.00x |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | 53.33x |
| Sep 2024 | 81.10x |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$2.2B
market value at close 2026-10-26 on 2026-07-31 shares, plus LongTermDebt as filed 2026-06-30 (includes the current portion), minus cash 2026-06-30
Enterprise value SRPT
| FY Dec 2025 | $2.3B |
| FY Dec 2024 | $11.6B |
| FY Dec 2023 | $9.8B |
| FY Dec 2022 | $12.0B |
| FY Dec 2021 | $6.3B |
| Jun 2026 | $2.2B |
| Mar 2026 | $2.7B |
| Dec 2025 | $2.3B |
| Sep 2025 | $1.4B |
| Jun 2025 | $2.3B |
| Mar 2025 | $7.1B |
| Dec 2024 | $11.6B |
| Sep 2024 | $12.9B |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
+4.3%
TTM free cash flow over market value at close 2026-10-26
FCF yield SRPT
| FY Dec 2025 | -13.6% |
| FY Dec 2024 | -3.0% |
| FY Dec 2023 | -6.4% |
| FY Dec 2022 | -3.1% |
| FY Dec 2021 | -6.1% |
| Jun 2026 | +4.3% |
| Mar 2026 | +5.0% |
| Dec 2025 | -13.6% |
| Sep 2025 | -20.2% |
| Jun 2025 | -26.9% |
| Mar 2025 | -11.2% |
| Dec 2024 | -3.0% |
| Sep 2024 | -3.9% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
PEG, trailing SRPT
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2025-09 | 2024-12 | 2023-12 | |
|---|---|---|---|---|
| Revenue | $2.2B | n/a | $1.9B | $1.2B |
| Operating income | -$699.8M | n/a | $218.1M | -$267.8M |
| Net income | -$713.4M | n/a | $235.2M | -$536.0M |
| EPS (diluted) | -7.13 | n/a | 2.34 | -5.80 |
| Operating cash flow | -$205.5M | n/a | -$205.8M | -$501.0M |
| Cash | $801.3M | n/a | $1.1B | $428.4M |
| Long-term debt | $829.0M | $140.5M | $1.1B | $1.2B |
| Buybacks | $25.0M | n/a | $0 | $0 |
SEC XBRL, fiscal years, as known on 2026-10-28
SRPT Stock Sonar score 5/7 axes
Find similar shapesCompareSRPT ranks highest on institutional and government (83rd percentile) and profitability (79th), and lowest on risk and compliance (15th), among Pharma & Biotech peers.
5 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
SRPT filings, in plain words
Have members of Congress traded SRPT?
Yes, but not in the year to 2026-10-28; the latest on record is a sale by Gilbert Cisneros dated 2025-04-14.
Read the full summary
Members of Congress have disclosed trades in SRPT, none in the last year; the latest on record is a sale by Gilbert Cisneros dated 2025-04-14. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
